The effect of vitamin D on depression, anxiety and general health.

The effect of oral vitamin D on depression, anxiety and general health in menopausal women.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090810002324N18

Enrollment

Registered

2021-01-02

Start date

2021-01-10

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Anxiety. Condition 2: Depression. Condition 3: General health. Anxiety disorder due to known physiological condition

Interventions

Intervention 1: Intervention group:The participants will take weekly 50,000 units of vitamin D for a consequence of eight weeks. Intervention 2: Control group: The participants will take weekly a plac

Eligibility

Sex/Gender

Female

Age

45 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age 45 to 65 years. pass of at least one year since the last menstrual period. Body mass index less than 30 kg/m^2. Physical and mental health (according to personal reporting)

Exclusion criteria

Exclusion criteria: Vitamin D level above 30 nmol/L in the first blood sample. Confirmation of chronic kidney, liver, thyroid and parathyroid diseases by laboratory tests. Use of any hormone or herbal drug during the study period. Irregular consumption or missing even one dose of vitamin D or placebo.

Design outcomes

Primary

Measure	Time frame
Anxiety score. Timepoint: At the beginning of the study and before the initial sampling, then at the end of the study (8 weeks after taking the vitamin D or placebo). Method of measurement: Beck Anxiety Inventory.;Depression score. Timepoint: At the beginning of the study and before the initial sampling, then at the end of the study (8 weeks after taking the vitamin D or placebo). Method of measurement: Beck Depression Inventory.;General Health. Timepoint: At the beginning of the study and before the initial sampling, then at the end of the study (8 weeks after taking the vitamin D or placebo). Method of measurement: General Health Questionnaire (GHQ).	—

Measure

Time frame

Anxiety score. Timepoint: At the beginning of the study and before the initial sampling, then at the end of the study (8 weeks after taking the vitamin D or placebo). Method of measurement: Beck Anxiety Inventory.;Depression score. Timepoint: At the beginning of the study and before the initial sampling, then at the end of the study (8 weeks after taking the vitamin D or placebo). Method of measurement: Beck Depression Inventory.;General Health. Timepoint: At the beginning of the study and before the initial sampling, then at the end of the study (8 weeks after taking the vitamin D or placebo). Method of measurement: General Health Questionnaire (GHQ).

—

Secondary

Measure	Time frame
Frequency and severity of menopausal symptoms. Timepoint: At the beginning of the study and before the initial sampling, then at the end of the study (8 weeks after taking the drug or placebo). Method of measurement: The Menopause Rating Scale (MRS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Keshavarz

Iran University of Medical Sciences

Keshavarz.m@iums.ac.ir+98 21 4365 1813

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026